Drug name - Movantik

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7662365 REDHILL Polymer conjugates of opioid antagonists
Oct, 2022

(17 days from now)

US7786133 REDHILL Chemically modified small molecules
Sep, 2028

(5 years from now)

US9012469 REDHILL Crystalline naloxol-peg conjugate
Apr, 2032

(9 years from now)

CN1925875A REDHILL The Small Molecules Of Chemical Modification
Apr, 2013

(9 years ago)

CN101805343B REDHILL Chemically Modified Small Molecules
Dec, 2024

(2 years from now)

CN102895666B REDHILL Chemistry Modified Small Molecule
Dec, 2024

(2 years from now)

CN101805343A REDHILL Chemical Modified Small Molecule
Dec, 2024

(2 years from now)

CN102895666A REDHILL Chemically Modified Small Molecules
Dec, 2024

(2 years from now)

CN103237547A REDHILL Naloxol-Polyethlyene Glycol Conjugates
Sep, 2031

(9 years from now)

CN103237547B REDHILL Crystalline Naloxone Alcohol-Peg Conjugate
Sep, 2031

(9 years from now)

EP1436012B1 REDHILL Polymer Conjugates Of Opioid Antagonists
Oct, 2022

(17 days from now)

EP2939696A1 REDHILL Polymer Conjugates Of Opioid Antagonists
Oct, 2022

(17 days from now)

EP1436012A2 REDHILL Polymer Conjugates Of Opioid Antagonists
Oct, 2022

(17 days from now)

EP2939696B1 REDHILL Polymer Conjugates Of Opioid Antagonists
Oct, 2022

(17 days from now)

EP2905033B1 REDHILL Monodisperse Pegylated Naloxol Compositions
Dec, 2024

(2 years from now)

EP2905033A1 REDHILL Monodisperse Pegylated Naloxol Compositions
Dec, 2024

(2 years from now)

EP2604282A1 REDHILL Method For Preparing Of Monodisperse Oligo Ethylene Glycol
Dec, 2024

(2 years from now)

EP2604282B1 REDHILL Method For Preparing Of Monodisperse Oligo Ethylene Glycol
Dec, 2024

(2 years from now)

EP1694363B1 REDHILL Monodisperse Pegylated Naloxol Compositions
Dec, 2024

(2 years from now)

EP1694363A2 REDHILL Monodisperse Pegylated Naloxol Compositions
Dec, 2024

(2 years from now)

EP2621496A1 REDHILL Crystalline Naloxol-Peg Conjugate
Sep, 2031

(9 years from now)

EP2621496A4 REDHILL Crystalline Naloxol-Peg Conjugate
Sep, 2031

(9 years from now)

EP2992903A1 REDHILL Combination Of A Naloxol-Peg Conjugate And An Opioid Agonist
Sep, 2031

(9 years from now)

EP2992903B1 REDHILL Combination Of A Naloxol-Peg Conjugate And An Opioid Agonist
Sep, 2031

(9 years from now)

EP2992903B8 REDHILL Combination Of A Naloxol-Peg Conjugate And An Opioid Agonist
Sep, 2031

(9 years from now)

EP2621496B1 REDHILL Crystalline Naloxol-Peg Conjugate
Sep, 2031

(9 years from now)

EP2621496B2 REDHILL Crystalline Naloxol-Peg Conjugate
Sep, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617530 REDHILL Polymer conjugates of opioid antagonists Oct, 2022

(17 days from now)

US7056500 REDHILL Polymer conjugates of opioid antagonists Jun, 2024

(1 year, 8 months from now)

US8067431 REDHILL Chemically modified small molecules Dec, 2024

(2 years from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.